• Phosphatase Inhibitor Cocktail 3: Unlocking Ferroptosis Rese

  2026-05-03

  Discover how Phosphatase Inhibitor Cocktail 3 (100X in DMSO) empowers advanced phosphoprotein analysis by preserving phosphorylation during ferroptosis research. Explore new mechanistic insights and practical assay protocols for signaling studies.

• GANT61: Selective GLI Inhibitor for Tumor Growth Suppression

  2026-05-02

  GANT61 is a selective GLI transcription factor inhibitor with proven efficacy in inhibiting GLI-mediated transcription and suppressing tumor growth in preclinical cancer models. As a key tool in Hedgehog pathway research, GANT61 disrupts GLI1/2-driven oncogenic signaling, offering researchers a validated approach to study tumor immune evasion and resistance mechanisms.

• Phosphatase Inhibitor Cocktail 2: Unlocking Proteostasis in

  2026-05-01

  Explore how Phosphatase Inhibitor Cocktail 2 ensures robust protein phosphorylation preservation in neurodegeneration studies. This article reveals unique mechanistic and translational insights for advanced signaling analysis.

• Phosphatase Inhibitor Cocktail: Precision in Phosphorylation

  2026-05-01

  The Phosphatase Inhibitor Cocktail (2 Tubes, 100X) empowers researchers to preserve protein phosphorylation with unmatched specificity, ensuring high-fidelity immunoblotting and kinase assay data. Its dual-component design uniquely safeguards both serine/threonine and tyrosine phosphorylation, outperforming traditional single-tube solutions in translational and mechanistic research.

• Gramine: Precision Ferroptosis Induction in TNBC Research

  2026-04-30

  This thought-leadership article explores Gramine’s mechanistic role as a precision ferroptosis inducer in triple-negative breast cancer (TNBC) research. It offers translational researchers an evidence-based framework for leveraging Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) to interrogate the CUL3–MTDH ubiquitination axis, with strategic guidance on experimental design, competitive positioning, and future directions. The piece integrates recent mechanistic findings, highlights APExBIO’s research-grade Gramine, and positions this molecule as a transformative tool for dissecting ferroptotic vulnerabilities in aggressive cancer subtypes.

• Redefining mRNA Delivery: Mechanistic Insight into EZ Cap™ C

  2026-04-30

  Explore the molecular innovations behind EZ Cap™ Cy5 EGFP mRNA (5-moUTP), a Cy5-labeled mRNA enabling real-time delivery tracking and translation efficiency measurement. This article offers a mechanistic analysis, practical protocol guidance, and advanced application strategies not covered in prior reviews.

• Super-Enhancer RNA Drives NPC Metastasis via NPM1/c-Myc/NDRG

  2026-04-29

  This study uncovers how carcinogen-induced super-enhancer RNA (seRNA-NPCm) drives nasopharyngeal carcinoma (NPC) metastasis by orchestrating the NPM1/c-Myc/NDRG1 transcriptional axis. The findings elucidate a mechanistic link between chemical carcinogen exposure and metastatic gene regulation in NPC, with implications for biomarker development and molecular targeting.

• SepM Mutations in Streptococcus mutans: Functional Insights

  2026-04-29

  Liu et al. (2024) identify key SepM gene mutations in Streptococcus mutans clinical isolates that enhance the bacterium's inhibitory effect on Streptococcus gordonii. Their comprehensive molecular analysis reveals pH-dependent increases in mutant SepM protein affinity for CSP-21, with implications for understanding oral microbial interactions and caries progression.

• Zolmitriptan for Translational Migraine Research: Mechanisti

  2026-04-28

  This thought-leadership article explores Zolmitriptan's mechanistic basis as a 5-HT1B/1D/1F receptor agonist and provides strategic guidance for translational researchers. Integrating contemporary advances in serotonin receptor and lysosomal biology, it evaluates experimental design, protocol optimization, and the evolving landscape of migraine and cluster headache research. The article positions Zolmitriptan (SKU B2261, APExBIO) as a research-grade standard, contextualizing its use with evidence-based references and actionable workflow recommendations.

• VE-822 ATR Inhibitor: Enhancing Radiosensitization in PDAC

  2026-04-28

  VE-822, a potent and selective ATR inhibitor, transforms DNA damage response assays by improving sensitivity and reproducibility in pancreatic ductal adenocarcinoma (PDAC) research. Applied in optimized workflows, it enables robust chemoradiotherapy sensitization strategies while minimizing off-target toxicity.

• Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO): Usage Gu

  2026-04-27

  The Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) prevents unwanted protein degradation during extraction by inhibiting major protease classes while remaining compatible with mass spectrometry workflows. It should be used in cell and tissue lysate preparation where broad-spectrum, MS-compatible protease inhibition is required, but is not suitable for workflows dependent on AEBSF or for applications requiring metalloproteinase inhibition without the addition of EDTA.

• DOT1L Inhibition Mitigates Renal Fibrosis by Blocking Fibrob

  2026-04-27

  This study demonstrates that selective inhibition of the histone methyltransferase DOT1L, using EPZ5676, substantially attenuates renal fibrosis by suppressing fibroblast activation and epithelial-mesenchymal transition (EMT). The findings expand the known therapeutic potential of DOT1L inhibitors beyond oncology, highlighting a pivotal role in tissue fibrosis modulation.

• ALDH1A3 Knockdown Inhibits CD44 in Breast Cancer Stem Cells

  2026-04-26

  This study elucidates a regulatory pathway in breast cancer stem cells where ALDH1A3 knockdown increases miR-7, leading to decreased CD44 expression via the TGFBR2-Smad3 axis. These findings clarify the molecular basis for targeting the stem cell subset in breast cancer and suggest new avenues for therapeutic intervention.

• Protein Corona Shaping Nanoparticle Delivery and Expression

  2026-04-25

  Elizabeth Voke's dissertation reveals how protein corona formation on nanoparticles, particularly lipid nanoparticles (LNPs), fundamentally alters their uptake and mRNA expression in mammalian cells. By introducing a robust proteomics workflow, the study highlights the disconnect between nanoparticle internalization and functional delivery, emphasizing the need for mechanistic corona characterization in translational nanomedicine.

• Tin Mesoporphyrin IX: Precision Inhibition in Heme Oxygenase

  2026-04-24

  Tin Mesoporphyrin IX (chloride) from APExBIO delivers nanomolar-potency heme oxygenase inhibition, enabling reproducible, sensitive workflows for metabolic, virological, and oxidative stress research. With robust in vivo stability and clear troubleshooting metrics, this reagent empowers both foundational and translational studies across domains.

16365 records 1/1091 page Next 12345 下5页 Last page